Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) EBITDA Margin (2018 - 2025)

Sunshine Biopharma's EBITDA Margin history spans 9 years, with the latest figure at 21.98% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 1092.0% year-over-year to 21.98%; the TTM value through Dec 2025 reached 14.35%, up 475.0%, while the annual FY2025 figure was 14.35%, 475.0% up from the prior year.
  • EBITDA Margin reached 21.98% in Q4 2025 per SBFM's latest filing, down from 15.77% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 777.1% in Q4 2021 to a low of 15445.58% in Q1 2021.
  • Average EBITDA Margin over 5 years is 1572.81%, with a median of 23.11% recorded in 2024.
  • Peak YoY movement for EBITDA Margin: tumbled -1458447bps in 2021, then soared 1443842bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 777.1% in 2021, then crashed by -176bps to 590.65% in 2022, then skyrocketed by 98bps to 9.88% in 2023, then crashed by -233bps to 32.9% in 2024, then soared by 33bps to 21.98% in 2025.
  • Per Business Quant, the three most recent readings for SBFM's EBITDA Margin are 21.98% (Q4 2025), 15.77% (Q3 2025), and 7.29% (Q2 2025).